- The trend backdrop is active with a 14-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
CVS
GER
Week ended 07 Aug 2026
Weekly Investor Report
CVS Health Corporation · Healthcare · Healthcare Plans
Latest close
82.60 EUR
-9.8%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 9.8% above the Trend Line and sits at 67.3% of its 52-week range. The latest completed week returned -9.8%, after a -9.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 57/100.
Setup score
63
out of 100
Latest Close
82.60 EUR
7 Aug 2026
1W Return
-9.8%
latest completed week
4W Return
-9.4%
short-term follow-through
12W Return
-0.7%
quarterly tape
Trend Breadth
76.9%
40 of 52 weeks active
Volume Ratio
3.7x
vs 13-week average
- 4 reversal markers appear in the recent smart-money tape.
- The latest week was a sharp negative move.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-9.8%
Latest completed week; four-week move -9.4%.
Indicator stack
87/68
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
57/100
21 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 9.8% above the Trend Line and sits at 67.3% of its 52-week range. The latest completed week returned -9.8%, after a -9.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 3.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9712-week average 0.86
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.97Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers
No recent accumulation markers. 4 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -9.4% over four weeks, -0.7% over 12 weeks, and 53.4% over one year. The current trend has remained active for 14 consecutive weeks.
Performance by holding period
Active trend streak14 weeks
Active weeks in one year40
Trend breadth76.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.04Latest activity-pressure read.
Pressure change-7.7%Four-week change in activity pressure.
Leadership8.25Latest relative-leadership reading.
RS change-72.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality27/100Profitability and accounting quality. Underlying universe rank 74; rank 1 is best.
Momentum87/100Medium-term price momentum. Underlying universe rank 14; rank 1 is best.
Growth28/100Revenue and earnings growth. Underlying universe rank 73; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework71/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 36.0x Price divided by trailing earnings.
- Price / sales
- 0.3x Market value relative to trailing revenue.
- EV / EBITDA
- 15.7x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 13.9% Gross profit retained from each unit of revenue.
- Operating margin
- 2.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 1.8% Free cash flow generated from revenue.
- Return on invested capital
- 6.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 7.8% Latest one-year revenue growth.
- EPS growth
- -62.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 23.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 2.8% Cash dividends relative to market value.
- Buyback yield
- -0.3% Net share repurchases relative to market value.
- Shareholder yield
- 2.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 6.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment57/100
Weighted news tone is neutral across 21 relevant articles.
6 positive · 14 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-14.4%Distance below the 52-week high.
13-week volatility5.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+9.7%Week of 15 May.
Worst week-9.8%Week of 7 Aug.
Latest week-9.8%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains8
Flat weeks0
Modest losses8
Sharp losses3
Recent vol5.5%13-week weekly-return volatility.
Base vol4.3%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew3.5% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank74 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Healthcare Plans
4-week rank3 / 3
Group average-7.6%
Trend breadth100.0%
Trend100.0%active weekly trend signals
MD100.0%positive activity pressure
RS66.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape69/100
Trend, activity pressure, participation, and risk combine to a 69/100 tape read.
Indicator analysis83/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.97; 4 reversal markers Factors62/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 92 SVQF71/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 109.5 of 375 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment57/100Weighted news tone is neutral across 21 relevant articles.
CVS Health Stock Slips 5% Despite Beating Quarterly Estimates and Raising Annual Guidance Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 82.60 EUR | -9.8% | 75.20 EUR | 59.89 EUR | 1.04 | 8.25 | 4.4K | On |
| 31 Jul 2026 | 91.58 EUR | -3.1% | 74.69 EUR | 59.75 EUR | 1.32 | 24.00 | 1.4K | On |
| 24 Jul 2026 | 94.50 EUR | 0.4% | 73.87 EUR | 59.54 EUR | 1.32 | 31.85 | 1.7K | On |
| 17 Jul 2026 | 94.14 EUR | 3.2% | 72.89 EUR | 59.32 EUR | 1.26 | 34.30 | 1.1K | On |
| 10 Jul 2026 | 91.18 EUR | 1.2% | 71.94 EUR | 59.10 EUR | 1.13 | 30.35 | 664 | On |
| 3 Jul 2026 | 90.13 EUR | -1.7% | 71.13 EUR | 58.87 EUR | 1.10 | 26.56 | 0 | On |
| 26 Jun 2026 | 91.68 EUR | 8.0% | 70.25 EUR | 58.66 EUR | 1.09 | 35.65 | 872 | On |
| 19 Jun 2026 | 84.90 EUR | -4.1% | 69.46 EUR | 58.42 EUR | 1.02 | 25.27 | 0 | On |
| 12 Jun 2026 | 88.56 EUR | 6.4% | 68.83 EUR | 58.24 EUR | 1.13 | 33.47 | 238 | On |
| 5 Jun 2026 | 83.24 EUR | 6.6% | 68.09 EUR | 58.03 EUR | 1.19 | 25.91 | 650 | On |
| 29 May 2026 | 78.08 EUR | -3.3% | 67.53 EUR | 57.87 EUR | 1.30 | 17.47 | 1.7K | On |
| 22 May 2026 | 80.76 EUR | -2.9% | 67.11 EUR | 57.73 EUR | 1.15 | 23.34 | 1.1K | On |
| 15 May 2026 | 83.20 EUR | 9.7% | 66.72 EUR | 57.57 EUR | 0.71 | 33.11 | 1.8K | On |
| 8 May 2026 | 75.84 EUR | 6.9% | 66.22 EUR | 57.40 EUR | 0.14 | 20.50 | 5.2K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.